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ABSTRACT 
Sea lice (Copepoda, Caligidae) are the most widely distributed marine pathogens in the salmon 
industry. Vaccination is considered an efficient, environmentally safe and economically sustainable 
alternative for control of ectoparasite infestations. Although emerging sea lice proteins have been 
identified recently, and have been proposed as potential targets for generating protective molecules, 
only a limited number of them have been evaluated in vaccine trials with unsuccessful results. On 
the other hand, more than 80 proteins are found in eukaryotic ribosomes. The protein P0 is essential 
for the assembly of the 60S ribosomal subunit and essential for cell viability. A vaccination-
challenge trial with an immunogenic peptide of Rhipicephalus sanguineus protein P0 reduced 
survival of ticks with an overall efficacy of 90%, suggesting that it might be a promising antigen 
candidate for the control of ectoparasite. We have identified an immunogenic region of the 
ribosomal protein P0 from Caligus rogercresseyi and Lepeophtheirus salmonis that is not very 
conserved compared to host P0. We developed several vaccine candidates based on this peptide and 
produced in E. coli. These antigens were able to elicit a high specific antibody response after 
intraperitoneal (ip) immunization using tilapia as teleost fish model. It has been shown that ip 
immunization with some antigens cannot significantly reduce larval lice numbers despite enhanced 
specific antibody titers were raised. In this context, we have been developed for first time several 
tools to monitor tilapia immune response (IgT, IFN-γ, IL-4, CD154) to vaccination in order to 
perform a more complete evaluation of the impact of the vaccinate candidates on the fish immune 
system. These findings will be finally validated in an immunization-challenge trial in Salmo salar. 
The overall results are relevant in the development of an effective vaccine against sea lice. 
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